Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03668600 · ClinicalTrials.gov registry record · Phase 3
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
A Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT03668600: Clinical Trial Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
NCT03668600 is a Phase 3 study that was terminated before completion, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 230 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03668600, a Phase 3 study, was terminated before completion, sponsored by Naurex, Inc, an affiliate of Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
Primary Outcome
A Treatment Emergent Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. An Adverse Drug Reaction was a harmful and unintended reaction that is incurred during routine administration or use of the drug, whose causal relationship with the drug cannot be excluded.
Interventions
- DRUG Rapastinel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 3 |
Why NCT03668600 stopped before completion
NCT03668600 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Rapastinel is the first listed.
NCT03668600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03668600 about?
NCT03668600 is a clinical study titled "Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)". Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
What is the current status of trial NCT03668600?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2018-08-23. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT03668600?
The interventions under investigation include: Rapastinel (DRUG).
Who is sponsoring clinical trial NCT03668600?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03668600's enrollment target sits among peer trials
230 1304th of 2000 higher than 692 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI